EnClear Therapies is a Cambridge, MA–based early-stage neurotechnology company led by CEO Anthony DePasqua. Its flagship product, the EnTrega CSF management platform, is designed to optimize therapeutic delivery and patient care in neuro-oncology and other central nervous system diseases. The company intends to use newly raised funds to expedite development within the Neuro‑Oncology field and to bolster its pre-clinical programs. EnClear has received more than $5M in non-dilutive SBIR funding from NINDS and NCI, which has supported its preclinical progress. It also reports strategic partnerships within the pharmaceutical sector to advance its technology toward clinical application. The company is focused on translating its neurotechnological strategies into improved CNS disease treatments. EnClear Therapies develops a proprietary device-based therapeutic platform that focuses on removing toxic proteins from cerebrospinal fluid (CSF). The company’s system is designed for delivery and monitoring of CSF and aims to aid treatment of neurodegenerative diseases. Its initial product efforts target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). EnClear intends to use new funding to move its therapeutic system into a first-in-human clinical trial in ALS. The company also plans to expand the platform into additional applications and pursue strategic partnerships. EnClear is led by CEO and co-founder Anthony DePasqua and is based in Cambridge, Mass. EnClear Therapies is a Cambridge, MA-based biotechnology company developing neurology-focused, device-based systems that remove toxic proteins and provide closed-loop delivery and monitoring of cerebrospinal fluid (CSF). Its platform aims to treat neurodegenerative diseases by directly clearing pathogenic proteins from CSF while enabling closed-loop therapeutic delivery and monitoring. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). EnClear intends to use the proceeds from its seed financing to advance development of these therapies. In March 2019 it secured approximately $2m in seed funding from several investors. Leadership includes CEO and co-founder Anthony DePasqua and newly hired Kevin Kalish as Vice President of Research and Development.

Total raised

$12M

Funding rounds

3

Latest round

Series A

Latest activity

Feb 2020